

Maxvax Biotechnology, www.maxvax.cn, founded 2016, privately held, HQ: Seattle, WA, Series A funding sought, \$40M round, please contact: Alex Chen, Alex.Chen@maxvax.cn

1. About Maxvax

Maxvax Biotechnology is a late clinical stage vaccine company headquartered in Chengdu, China with operations in several cities in China and Seattle, USA. Maxvax is developing novel adjuvant systems and vaccines to address unmet needs of global public health.

2. Manufacturing Facilities

Maxvax has GMP compliant commercial scale facilities for producing adjuvant raw materials, adjuvant formulations, and vaccines for clinical trials and commercialization.

3. Shingles Vaccine

Maxvax's lead product candidate is our shingles vaccine, MKK100. Phase 2 interim data shows improved safety/tolerability and gE antibody responses non-inferior to Shingrix in a post-hoc analysis. A Phase 3 efficacy trial is scheduled to start in China in Q2/Q3 2024. A Phase ½ safety and immunogenicity trial in Australia is planned.

4. Adjuvant Technologies


Maxvax has in-house produced adjuvant raw materials and adjuvant formulations (Table 1) for vaccine development.

Table 1: Adjuvant formulations (GMP)

Formulation codes	Description	Properties
MA130 or MA135	Oil-in-water emulsions similar to those used in licensed influenza vaccines	Enhance antibody responses
MA103	Saponin in a liposomal formulation	Enhance antibody and CD4 ⁺ T-cell responses
MA105	Saponin and a TLR Agonist in a liposomal formulation	Enhance antibody, CD4 ⁺ , and possibly CD8 ⁺ T-cell responses

5. Vaccine pipeline

Maxvax has a pipeline of vaccine candidates in preclinical and clinical development. Most candidates are based on recombinant proteins and novel adjuvants. Maxvax plans to market certain vaccine candidates to global markets including the US.



6. Partnering opportunities

- 1) Adjuvant raw materials and adjuvant formulations available for research and vaccine development.
- 2) Co-development, registration, and distribution of Shingles and trivalent vaccine in regions outside of China.
- 3) Maxvax is seeking investments to establish a separate US entity and perform clinical trials outside of China.